{
  "ticker": "IVX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960890",
  "id": "02960890",
  "pages": 44,
  "price_sensitive": false,
  "date": "20250623",
  "time": "0942",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l045p2b6wgbk.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Capital Raising Announcement**  \n- **Structure**: Pro rata non-renounceable entitlement offer of Loyalty Options + contingent Piggy-Back Options.  \n  - **Loyalty Options**: 77 new options for every 100 existing shares at **A$0.015 per option**.  \n  - **Piggy-Back Options**: 1 free option for every 2 Loyalty Options exercised by 31 Dec 2025 (exercise price: A$0.21).  \n- **Total Raising**: ~**A$1M** (initial offer) + up to **A$9.2M** (if all Loyalty Options exercised) + **A$6.9M** (if all Piggy-Backs exercised).  \n- **Use of Funds**:  \n  - R&D (51%) \u2013 NMSC and anogenital cancer trials.  \n  - Working capital (36%).  \n  - Offer costs (13%).  \n\n#### **Key Dates**  \n- **Ex-date**: 25 Jun 2025.  \n- **Record Date**: 26 Jun 2025.  \n- **Offer Opens**: 1 Jul 2025.  \n- **Offer Closes**: 10 Jul 2025.  \n- **Loyalty Options Issue Date**: 17 Jul 2025.  \n\n#### **Capital Structure Impact**  \n- **Post-Offer**: ~84.7M shares outstanding; ~84.4M options (existing + new Loyalty Options).  \n- **If Fully Exercised**:  \n  - **Loyalty Options**: +65.8M shares (A$9.2M raised).  \n  - **Piggy-Backs**: +32.9M shares (A$6.9M raised).  \n\n#### **Key Risks**  \n- **Dilution**: Non-participating shareholders face dilution.  \n- **R&D Dependence**: Success hinges on clinical trials (NMSC and anogenital cancer).  \n- **Revenue Uncertainty**: No current product revenue; future funding needs likely.  \n- **Underwritten**: Fully underwritten by Blue Ocean Equities (fees: 3.5% management + 2.5% selling).  \n\n#### **Governance**  \n- **Director Participation**: Chairman Thian Chew committed to full entitlement uptake; sub-underwriting A$150k via Polar Ventures.  \n- **Substantial Holders**: Honsue Cho group holds 13.73% pre-offer; potential post-offer voting power up to 29.51% if all options exercised.  \n\n**No material operational updates beyond disclosed clinical trial progress.**  \n\n*(Note: Omitted routine disclosures, legal boilerplate, and non-essential director interests.)*",
  "usage": {
    "prompt_tokens": 28057,
    "completion_tokens": 575,
    "total_tokens": 28632,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-22T23:50:44.163602"
}